Telemetry devices
This article was originally published in The Gray Sheet
Executive Summary
FDA will begin inspecting manufacturers of wireless telemetry devices after Dec. 8, 2000 to "verify that appropriate action is being taken to assess and mitigate" electromagnetic interference (EMI) risks, according to Office of Compliance guidance released Oct. 20. The guidance recommends that manufacturers utilize the Wireless Medical Telemetry Service created by the Federal Communications Commission to protect against interference, as well as conduct a risk analysis. A guidance on when to submit a new 510(k)s for changes to a telemetry device will be made available
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.